Cabozantinib as subsequent therapy to an immune checkpoint inhibitor based therapy in renal cell carcinoma, phase 2, multicenter, open label, interventional study (AT ASIA)
- Conditions
- Neoplasms
- Registration Number
- KCT0005866
- Lead Sponsor
- Asan Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 201
1.Documented histological or cytological diagnosis of advanced renal cell cancer with or without clear-cell component with an exception of collecting duct carcinoma.
2.Measurable disease per Response Evaluation Criteria In Solid Tumor (RECIST) version 1.1, as determined by the investigator.
3.Recovery to baseline or = Grade 1 CTCAE v.5.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
4.Age eighteen years or older on the day of consent.
5.Karnofsky Performance Status (KPS) score of = 70%.
6.Adequate organ and marrow function, based upon meeting all of the following laboratory criteria within ten days before randomization:
a.Absolute neutrophil count (ANC) = 1500/mm3
b. Platelets = 100,000/mm3
c.Hemoglobin = 9 g/dL
d.Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3.0 ? upper limit of normal.
e.Total bilirubin = 1.5 ? the upper limit of normal. For subjects with Gilbert’s disease = 3 mg/dL (= 51.3 µmol/L).
f.Serum creatinine = 2.0 ? upper limit of normal or calculated creatinine clearance
= 30 mL/min (= 0.5 mL/sec), calculated with one of the three formulae as follows, Cockroft-Gault equation, CKD-EPI, or MDRD GFR equation (see Table 5-2).
g.Urine protein-to-creatinine ratio (UPCR) = 1 mg/mg (= 113.2 mg/mmol) creatinine or 24-hour urine protein < 1 g.
7.Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.
8.Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom).
9.Female subjects of childbearing potential must not be pregnant at the screening. Females of childbearing potential are defined as premenopausal females capable of becoming pregnant (i.e., females who have had any evidence of menses in the past 12 months, except for those who had a prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression, or other reasons.
10.Cohort-Specific Criteria
Cohort 1
a.Must have received nivolumab and ipilimumab combination as the first-line systemic treatment
b.Subjects who experienced disease progression on nivolumab and ipilimumab combination or unacceptable toxicities.
Cohort 2
a.Must have received pembrolizumab plus axitinib, pembrolizumab plus Lenvatinib, or avelumab plus axitinib combination as the first-line systemic treatment
b.Subjects who experienced disease progression on nivolumab and ipilimumab PD-1/PD-L1 inhibitors with VEGFR TKI combination or unacceptable toxicities.
Cohort 3
a.Must have received VEGFR TKI (e.g., sunitinib, axitinib, pazopanib, or sorafenib) as the first-line systemic treatment and sequential PD-1 antibody or PD-L1 antibody, e.g., Pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, PDR001.
b.Subjects who experienced disease progression on second-line PD-1 or PD-L1 antibody or unacceptable toxicities.
1.Prior treatment with cabozantinib.
2.Treated with any other investigational medicinal product (IMP) within the last 30 days before screening
3.For cohort 1 & 2, concurrent involvement participation in any investigational study.
4.For cohort 3, participation in cabozantinib Post Marketing Survey (rPMS) during the study
5.Radiation therapy for bone metastasis within one week, any other external radiation therapy within two weeks before randomization. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
6.Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least one month before randomization. Eligible subjects must be neurologically asymptomatic at the time of enrollment.
7.Concomitant anticoagulation at therapeutic doses with oral anticoagulants (e.g., warfarin, direct thrombin, and Factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel).
Note: Low-dose aspirin for cardioprotection (per locally applicable guidelines), low-dose warfarin (< 1 mg/day), and low dose, low molecular weight heparins (LMWH) are permitted. Anticoagulation with therapeutic doses of LMWH is allowed in subjects without radiographic evidence of brain metastasis, who are on a stable dose of LMWH for at least 12 weeks before randomization, and who have had no complications from a thromboembolic event or the anticoagulation regimen.
8.The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
a.Cardiovascular disorders:
i.Symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmias.
ii.Uncontrolled hypertension defined as sustained BP > 150 mm Hg systolic or
>?100 mm Hg diastolic despite optimal antihypertensive treatment.
iii.?Stroke (including TIA), myocardial infarction, or other ischemic event, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 6 months before randomization.
b.Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:
i.?Tumors invading the GI-tract, active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic or biliary duct, or gastric outlet obstruction.
?Abdominal fistula, gastrointestinal perforation, bowel obstruction, or intra-abdominal abscess within 6 months before randomization.
Note: Complete healing of an intra-abdominal abscess must be confirmed before randomization.
c.Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage) within 3 months before enrollment.
d.Cavitray lung lesions or documented endobronchial lesions
d.e.Lesions invading major pulmonary blood vessels.
e.f.Other clinically significant disorders such as:
i.?Active infection requiring systemic treatment, infection with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)- related illness.
ii.?Serious non-healing wound/ulcer/bone fracture.
iii.?Malabsorption syndrome.
iv.?Moderate to severe hepatic impairment (Child-Pugh B or C).
v.?History of solid organ transplantation.
9.Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) withi
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective response rate (ORR), per Response Evaluation Criteria In Solid Tumor (RECIST) version1.1, per investigator assessment
- Secondary Outcome Measures
Name Time Method Time to response, per RECIST version1.1, per investigator assessment;Duration of response (DoR), per RECIST version 1.1, per investigator assessment;Progression-free survival (PFS), per RECIST version 1.1, per investigator assessment;Safety